Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Supernus Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company focused on the development and commercialization of central nervous system (CNS) therapies. The company operates within the biopharmaceutical and neurology-focused pharmaceutical industries, targeting conditions such as attention-deficit/hyperactivity disorder (ADHD), epilepsy, and other neurological disorders. Supernus primarily generates revenue through branded prescription medications sold in the United States, with a strategy centered on differentiated formulations of established compounds.
The company’s core commercial products include Qelbree for ADHD and extended-release epilepsy treatments such as Trokendi XR and Oxtellar XR. Supernus is positioned around proprietary formulation technologies designed to improve dosing convenience, tolerability, and patient adherence. Founded in 2005, Supernus evolved from a development-stage company into a fully integrated commercial organization following the approvals and launches of its CNS products in the 2010s, expanding further through targeted acquisitions.
Business Operations
Supernus operates primarily as a single-reportable operating segment focused on branded CNS pharmaceuticals, with revenue derived from product sales and, to a lesser extent, royalties and licensing arrangements. Commercial operations are concentrated in the United States, supported by in-house sales, marketing, medical affairs, and regulatory capabilities. The company relies on third-party manufacturers for drug production while retaining control over formulation technology and commercialization strategy.
In addition to its internal portfolio, Supernus manages assets obtained through acquisitions, including Adamas Pharma, LLC, which added movement disorder products and intellectual property. Certain legacy products acquired through Adamas are no longer actively promoted by Supernus; public disclosures indicate changes in ownership or royalty-based arrangements, though specific current commercialization responsibility for some assets is data inconclusive based on available public sources.
Strategic Position & Investments
Supernus’s strategy emphasizes organic growth from its ADHD franchise, lifecycle management of epilepsy products, and disciplined capital deployment. The company has historically invested in late-stage clinical development, formulation innovation, and selective acquisitions that leverage its CNS commercial infrastructure. Qelbree represents a central growth driver, supported by expanded age indications and increased promotional investment.
Strategic transactions have included the acquisition of Adamas Pharmaceuticals, Inc. in 2021, which broadened Supernus’s CNS portfolio and generated both operating assets and financial optionality. Supernus has also evaluated early- and mid-stage CNS programs through internal research and external partnerships, though its primary focus remains on commercially executable assets rather than high-risk discovery research.
Geographic Footprint
Supernus is headquartered in North America, with its corporate headquarters located in the United States. The company’s commercial activities are overwhelmingly U.S.-centric, reflecting its focus on FDA-approved products and the U.S. prescription market. International exposure is limited and primarily related to intellectual property holdings, regulatory rights, or subsidiary structures rather than direct product commercialization.
The company maintains certain international subsidiaries, including entities in Europe, that support intellectual property management and corporate structuring. However, Supernus does not currently operate a large-scale branded commercial presence outside the United States, and international revenue contribution is not material based on publicly available disclosures.
Leadership & Governance
Supernus is led by an experienced executive team with backgrounds in CNS drug development, commercialization, and corporate finance. The leadership philosophy emphasizes capital discipline, regulatory execution, and focused portfolio management within neurology and psychiatry.
Key executives include:
- Jack Khattar – President and Chief Executive Officer
- David G. Keenan – Executive Vice President and Chief Financial Officer
- Andrew J. Krauss – Executive Vice President and Chief Medical Officer
The company is governed by a board of directors with experience across pharmaceuticals, biotechnology, and public company oversight, aligning management incentives with long-term shareholder value and compliance with U.S. public company governance standards.